# V31 iter10 — 完整 50×11 逐字段审查 (vLLM vs HF vs 原文)

> 50 matched samples × 11 fields = 550 field-instances
> 每个 field 列出完整 vLLM 和 HF 值，标注判定

## 总结

| 指标 | 数量 | 占比 |
|------|------|------|
| 总字段 | 550 | 100% |
| vLLM ≥ HF | 142 | 25% |
| HF > vLLM (⚠️) | 61 | 11% |
| 相同/相近 | 347 | 63% |
| All-win ROWs | 14/50 | 28% |

All-win: [1, 3, 6, 8, 9, 14, 30, 33, 41, 42, 49, 52, 61, 97]


---
## ROW 1
A/P摘要: "Assessment / Plan:    1.  Stage II right breast cancer s/p right mastectomy with sentinel node in June 2013 ( 2.4 and 2.3 cm tumors, node negative ER

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+ grade 2 invasive ductal carcinoma with metastatic recurrence, HER2-
- HF: ER+/PR+ invasive ductal carcinoma, HER2-

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: ≈ 相近
- vLLM: Yes, to lungs, peritoneum, liver, ovary
- HF: Yes, to lungs, peritoneum, liver, and ovary

**response_assessment**: ✅ vLLM更详细
- vLLM: The cancer is currently progressing. The CT chest, abdomen, and pelvis performed on 12/24/2019 show widespread metastases consistent with metastatic breast carcinoma. There is right axillary adenopathy with a 1.8 cm spiculated mass along the superolateral margin of the right breast implant, suspicio
- HF: The cancer is currently progressing. Evidence includes widespread metastases consistent with metastatic breast carcinoma, right axillary adenopathy with a 1.8 cm spiculated mass, multiple small pulmonary nodules, large hepatic masses, peritoneal carcinomatosis, and mildly enlarged and hyperdense ova

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ≈ 相近
- vLLM: If the patient is HR+/her 2 negative on biopsy will recommend ibrance and [REDACTED].
- HF: If the patient is HR+/HER2 negative on biopsy, will recommend ibrance and [REDACTED].

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ✅ vLLM独有
- vLLM: No specific genetic or molecular tests are planned. An appointment is scheduled for a biopsy to confirm the status of HR and HER2.
- HF: (空)

**medication_plan**: ✅ vLLM更详细
- vLLM: If HR+/HER2 negative on biopsy, will recommend ibrance and unspecified agent.
- HF: If HR+/HER2 negative on biopsy, will recommend Ibrance and [REDACTED].

**→ ALL-WIN ✅**

---
## ROW 2
A/P摘要: "ASSESSMENT & PLAN  ***** ***** is a 44 y.o. female with ***** Syndrome and early stage endometrial and colon cancer and now with newly diagnosed meta

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: Triple negative invasive ductal carcinoma (TNBC) with metastatic recurrence
- HF: ER-/PR-/HER2- triple negative invasive ductal carcinoma

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: ✅ vLLM更详细
- vLLM: Yes, to liver, bone, chest wall, and possibly intracranial/skull base
- HF: Yes, to liver, bone, and chest wall

**response_assessment**: ⚠️ HF更长(312 vs 241)
- vLLM: MRI lumbar spine shows numerous bone marrow replacing lesions in the lumbar spine and pelvis, most pronounced at S1 with endplate fracture. No specific imaging or tumor marker evidence is provided to assess the current response to treatment.
- HF: Metastatic breast cancer is progressing. Scans show numerous bone marrow replacing lesions in the lumbar spine and pelvis, most pronounced at S1 with endplate fracture. Chest wall more tender, erythematous, and edematous, which is worrisome for infection. Back pain is worse, possibly due to disease 

**current_meds**: ≈ 相近
- vLLM: irinotecan
- HF: Irinotecan

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Due to her poor tolerance, irinotecan will be changed to every other week with an increased dose to 150mg/m2 on days 1 and 15 every 28 days. She urgently needs to get in with Radiation Oncology for a referral to Dr.; potassium, brace, home health
- HF: Due to poor tolerance, irinotecan will be changed to every other week with an increased dose to 150mg/m2 on days 1 and 15 every 28 days.

**imaging_plan**: = (完全一致)

**lab_plan**: ≈ 相近
- vLLM: Monitor with ALT, hepatitis B surface antigen and HBV DNA every 4 months. Scans again in 3 months, due September 2019.
- HF: Monitor with ALT, hepatitis B surface antigen and HBV DNA every 4 months without starting prophylaxis, next due October 2019

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ⚠️ HF更长(161 vs 104)
- vLLM: [REDACTED] 30mg TID, Flexeril TID, oxycodone 5mg prn, Cymbalta for RLS, Effexor-XR increased to 75 mg qd
- HF: Doxycycline 100mg BID x 7d, [REDACTED] 30mg TID, Flexeril TID, oxycodone 5mg prn, Effexor-XR 75 mg qd, 500ml NS IV, 40 mEq PO potassium, 1 unit pRBC transfusion.


---
## ROW 3
A/P摘要: "Assessment / Plan:    1. Stage IIA right IDC of the breast 1.7 cm, node positive, HR+, her 2 neu negative by FISH.    2. ***** sent and is pending. W

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: HR+, HER2 neu negative grade 2 invasive ductal carcinoma
- HF: ER+/PR+/HER2- invasive ductal carcinoma

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: = (完全一致)

**imaging_plan**: ✅ vLLM更详细
- vLLM: PET scan follow up after PET results are back.
- HF: PET imaging follow up after results are back.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)

**→ ALL-WIN ✅**

---
## ROW 5
A/P摘要: "Assessment \\Plan :    1. ***** ***** is a 31 y.o. premenopausal patient with a history of a Stage III *****+/*****- IDC of the left breast (*****/**

**Type_of_Cancer**: ≈ 相近
- vLLM: ER+/PR+/HER2- grade 2 invasive ductal carcinoma (micropapillary features) with metastatic recurrence (left cervical LN)
- HF: ER+/PR+/HER2- invasive ductal carcinoma (micropapillary features) with metastatic recurrence (left cervical LN) ER+/PR+/HER2-

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: ⚠️ HF更长(71 vs 44)
- vLLM: Yes, to left internal mammary LN and sternum
- HF: Yes, to left cervical lymph nodes and left internal mammary lymph nodes

**response_assessment**: ⚠️ HF更长(698 vs 583)
- vLLM: CT neck and CAP on 08/23/19 showed decreased size of left cervical chain LNs (largest - 1.8 cm -> 1.2 cm) and stable borderline enlargement of mediastinal LN (right upper paratracheal LN (0.9 cm)). Decreased dominant more anterior nodule (3.2 x 2.6 cm -> 2.5 x 1.7 cm) in the skin of lateral left bre
- HF: CT neck and CAP: decreased size of left cervical chain LNs (largest - 1.8 cm -> 1.2 cm) as well as additional bilateral subcentimeter lymph nodes that did not meet criteria for LAD; stable borderline enlargement of mediastinal LN (ex - right upper paratracheal LN (0.9 cm), stably enlarged left IM LN

**current_meds**: ≈ 相近
- vLLM: anastrozole, palbociclib, goserelin
- HF: anastrozole, palbociclib, leuprolide

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(201 vs 157)
- vLLM: Continue current therapy including leuprolide, anastrozole, and palbociclib. Radiation referral for symptomatic disease in her left neck and brachial plexus.
- HF: Continue current therapy with leuprolide, anastrozole, and palbociclib. Radiation referral for symptomatic disease in her left neck and brachial plexus. Labs monthly on the day of her lupron injection.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)


---
## ROW 6
A/P摘要: "Assessment and Plan:  Patient Active Problem List   Diagnosis   \u0007 Bipolar 2 disorder (HCC)   \u0007 Insomnia   \u0007 Breast Cancer Right   \u00

**Type_of_Cancer**: ≈ 相近
- vLLM: ER+/PR+/HER2- grade 1 invasive ductal carcinoma with extensive DCIS
- HF: ER+/PR+/HER2- grade 1 IDC (invasive ductal carcinoma) with extensive DCIS

**Stage_of_Cancer**: ✅ vLLM独有
- vLLM: Stage IA (inferred from pT1 N0)
- HF: (空)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: Recovering nicely with some residual nerve irritation, mild edema, resolving ecchymosis in the inferior medial aspect of the right breast, and one stitch at 12 o'clock in the right breast.
- HF: On treatment; response assessment not available from current visit.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Discussed starting letrozole today. [REDACTED] try to continue the [REDACTED] for at least 3 years and can sequence with tamoxifen.
- HF: Discussed starting letrozole today. Plan to continue letrozole for at least 3 years and can sequence with tamoxifen.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Start letrozole today. Continue [REDACTED] for at least 3 years and can sequence with tamoxifen. Start [REDACTED] per her request. Estradiol monthly. Gabapentin prescribed as needed per her request.; also: zoladex
- HF: Start letrozole today. Continue [REDACTED] for at least 3 years and can sequence with tamoxifen. Gabapentin prescribed as needed. Estradiol monthly.

**→ ALL-WIN ✅**

---
## ROW 7
A/P摘要: "IMP  1. MBC, recurrent and metastatic \n since 2008. ***** by IHC, *****/***** or possibly *****. Recent PET-CT ***** as probable PD. However, eviden

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER-/PR- IDC (invasive ductal carcinoma) with metastatic recurrence (left supraclavicular node and mediastinal disease), HER2+
- HF: ER-/PR-/HER2+ invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Originally Stage II, now metastatic (Stage IV)
- HF: Originally Stage II, now Stage IV

**Distant Metastasis**: ≈ 相近
- vLLM: Yes, to left supraclavicular node and mediastinum
- HF: Yes, to the left supraclavicular node and mediastinum

**response_assessment**: ⚠️ HF更长(288 vs 237)
- vLLM: Probable mild progression in the left breast and possibly the left anterior chest wall. CT shows increased size of left breast tail nodule with SUV 2.1 (was 1.8). [REDACTED] persistently elevated at 14.8 but not increased since previous.
- HF: Probable mild progression in the left breast and possibly the left anterior chest wall. CT shows increased size of left breast tail nodule with SUV 2.1 (previously 1.8). [REDACTED] persistently elevated at 14.8 but not increased since previous. Pt does note some L CW discomfort, however.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Do not consider hormonal therapy at this time. Discussed current clinical trial possibilities, here at [REDACTED] and nationally.; physical therapy
- HF: Do not consider hormonal therapy at this time.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Recommend [REDACTED] as next line of treatment. Recheck [REDACTED] prior to starting new regimen. Do not consider hormonal therapy at this time.; also: herceptin
- HF: Discontinue current regimen including [REDACTED]/Herceptin/Taxotere. Recommend [REDACTED] as the next line of treatment.


---
## ROW 8
A/P摘要: "Assessment and Recommendations:  29 y.o. premenopausal patient with a history of clinical stage III *****-/*****+ IDC of the left breast, who receive

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER-/PR-/HER2+ (IHC 3+, FISH ratio 5.7) grade 3 invasive ductal carcinoma
- HF: ER-/PR-/HER2+ (IHC 3+, FISH ratio 5.7) invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Originally Stage III, now post-neoadjuvant with 3 of 28 LN positive for HER2+ adenocarcinoma
- HF: Stage III

**Distant Metastasis**: = (完全一致)

**response_assessment**: ≈ 相近
- vLLM: The patient received neoadjuvant TCHP followed by left lumpectomy and ALND. Pathological examination revealed no residual invasive carcinoma in the breast, with 3 of 28 lymph nodes positive for HER2+/ER- adenocarcinoma, the largest being 2.4 cm with extranodal extension. This indicates a partial res
- HF: The patient has completed neoadjuvant therapy and had a left lumpectomy/ALND. The surgical pathology showed no residual disease in the breast but 3 of 28 lymph nodes were positive for HER2+/ER- adenocarcinoma, with the largest lymph node 2.4 cm and extranodal extension. PET/CTs on 02/23/19 and 06/22

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ≈ 相近
- vLLM: adjuvant AC x 4 cycles, to be followed by T-DM1; radiation
- HF: adjuvant AC x 4 cycles, to be followed by T-DM1 and radiation

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)

**→ ALL-WIN ✅**

---
## ROW 9
A/P摘要: "Assessment \\Plan :    1.  Stage II right IDC of the breast HR+/ her 2 neu negative.    2.  ***** is high risk. S/p 4 cycles of ***** and weekly taxo

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR-/HER2- grade 2 invasive ductal carcinoma
- HF: ER+/PR-/HER2- invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Stage II (inferred from pT3 N1)
- HF: Stage II

**Distant Metastasis**: = (完全一致)

**response_assessment**: ≈ 相近
- vLLM: The surgical pathology showed a 3.84 cm residual invasive ductal carcinoma with 5% cellularity in the right breast after neoadjuvant chemotherapy. One lymph node showed metastatic carcinoma (0.21 cm) with extranodal extension, one node had isolated tumor cells, and another had micrometastatic carcin
- HF: The cancer has responded to neoadjuvant chemotherapy as evidenced by the surgical pathology showing a 3.84 cm residual tumor with 5% cellularity, one lymph node with macrometastases (0.21 cm) and extranodal extension, and one lymph node with micrometastases (0.025 cm). Treatment effect is present in

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ≈ 相近
- vLLM: Plan to start letrozole after radiation.
- HF: Radiation referral. Letrozole after radiation.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)

**→ ALL-WIN ✅**

---
## ROW 10
A/P摘要: "Assessment \\Plan :    1. Stage II left ***** of the breast HR + and her 2 negative s/p neoadjuvant letrozole April 2021. Low risk *****.   2.  S/p l

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: HR+ (ER+/PR+) HER2- grade 2 invasive ductal carcinoma
- HF: HR+ invasive ductal carcinoma, HER2-

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Stage II (inferred from 8.8 cm tumor with 20 lymph nodes involved)
- HF: Stage II

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: No specific evidence regarding the current response of the cancer is provided in the note. The note mentions that the patient has recovered well from surgery and does not need chemotherapy due to low risk, but there is no detailed information on imaging, measurements, or SUV values.
- HF: Low risk [REDACTED]. S/p left mastectomy with a 8.8.cm [REDACTED] with July 20 lymph nodes involved. S/p bilateral reductions with re excision for margins 08/07/2021.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(120 vs 89)
- vLLM: Continue letrozole. To have radiation to the left chest wall and surrounding lymph nodes.
- HF: She will continue on letrozole started April 2021. To have radiation to the left chest wall and surrounding lymph nodes.

**imaging_plan**: ✅ vLLM更详细
- vLLM: To have DEXA.
- HF: DEXA.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)


---
## ROW 11
A/P摘要: "ASSESSMENT & PLAN  Breast cancer metastasized to multiple sites  Exam stable  Mouth healing has thrush mycelex ***** qid  Having right leg pain worse

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: infiltrating ductal carcinoma with metastatic recurrence to bone, ER+ (inferred from letrozole), HER2: not tested
- HF: ER+/PR+/HER2- infiltrating ductal Carcinoma

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: Recent PET/CT showed increased metastatic activity and a left mandibular mass. No evidence of response to current treatment with Fulvestrant and Denosumab. Worsening numbness in right leg suggests possible progression or lack of response.
- HF: PET/CT showed increased metastatic activity and size of left mandibular mass. Imaging and exam suggest the cancer is progressing on current treatment with Faslodex and Denosumab.

**current_meds**: ✅ vLLM更详细
- vLLM: Fulvestrant, Denosumab
- HF: Faslodex, Denosumab

**goals_of_treatment**: = (完全一致)

**therapy_plan**: = (完全一致)

**imaging_plan**: ⚠️ HF更长(86 vs 47)
- vLLM: Will order PETCT to evaluate Femur and to toes.
- HF: Will order PETCT to evaluate Femur and to toes due to worsening numbness in right leg.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ≈ 相近
- vLLM: Continue on Faslodex and Denosumab. [REDACTED]-Mycelex [REDACTED] 5 times a day for 14 days to help with thrush. Salt and soda rinses.
- HF: Continue on Faslodex and Denosumab. [REDACTED]-Mycelex [REDACTED] 5 times a day for 14 days to help with thrush and salt and soda rinses.


---
## ROW 12
A/P摘要: "ASSESSMENT & PLAN  #. Metastatic breast cancer, St IV de *****.  ***** ***** is a 50 y.o. female with de ***** *****+/PR+/*****+ breast cancer to ***

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2+ (IHC 3+/FISH 15.April 10=5.4) invasive ductal carcinoma
- HF: ER+/PR+/HER2+ invasive ductal carcinoma

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ⚠️ HF更长(1227 vs 592)
- vLLM: MRI brain on 08/15/18 showed multiple very small new CNS lesions. CT CAP on 09/05/18 was stable. Recent MRI shows new lesions. CT shows only multiple bone sites, ? Active, no sx's and no evidence of PD. MRI brain on 09/05/18 showed no pleural effusion, no mediastinal lymphadenopathy, and stable appe
- HF: CT stable, MRI brain on 08/15/18 showed multiple very small new CNS lesions. CT CAP on 09/05/18 was stable. Recent MRI shows new lesions. MRI brain on 09/05/18 showed no pleural effusion, no mediastinal lymphadenopathy, and stable appearance of diffuse osseous metastatic lesions. CT A/P on 09/05/18 

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ≈ 相近
- vLLM: continue herceptin and unspecified agent; continue letrozole daily; continue off chemotherapy for now, due to intolerance to multiple agents; await GK / Radiation Oncology input, and potential plan for repeat GK
- HF: continue herceptin/[REDACTED] [REDACTED], continue letrozole qd, continue [REDACTED] q12 wks given stable bone status, continue off chemotherapy for now, await GK / Rad Onc input, and potential plan for repeat GK

**imaging_plan**: ≈ 相近
- vLLM: CT CAP every 4 months; will add bone scan with next eval in 4 mos; MRI brain every 4 months
- HF: CT CAP every 4 months, will add bone scan with next eval in 4 mos, MRI brain every 4 months

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ⚠️ HF更长(195 vs 145)
- vLLM: Continue herceptin and [REDACTED]; continue letrozole qd; continue [REDACTED] q12 wks given stable bone status; continue off chemotherapy for now
- HF: continue herceptin/[REDACTED] [REDACTED], continue letrozole qd, continue [REDACTED] now q12 wks given stable bone status, continue off chemotherapy for now due to intolerance to multiple agents.


---
## ROW 14
A/P摘要: "ASSESSMENT & PLAN    ***** ***** ***** is a 58 y.o. female with de ***** metastatic ER+ breast cancer to bone, liver and nodes who is currently on fa

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+ metastatic breast cancer, HER2-
- HF: ER+ breast cancer, HER2-

**Stage_of_Cancer**: ≈ 相近
- vLLM: Metastatic (Stage IV)
- HF: Stage IV (metastatic)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: Right breast nodules have slightly increased in size, with the largest measuring 14 mm, previously 10 mm. Hypodense liver lesion in segment 7 measuring 16 x 15 mm, previously 11 x 13 mm. New sclerotic foci within the L4 vertebral body, sacrum, and bilateral iliac bones. No evidence of new or worseni
- HF: The cancer is currently stable. No significant changes in imaging findings since last visit. On exam, no new masses, skin changes, or lymphadenopathy noted.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: = (完全一致)

**imaging_plan**: ≈ 相近
- vLLM: CT CAP and Total Spine MRI scheduled for May; Repeat total spine MRI in 6 weeks.
- HF: CT CAP and Total Spine MRI scheduled for May. Repeat total spine MRI in 6 weeks.

**lab_plan**: ✅ vLLM更详细
- vLLM: She has been instructed to have her labs drawn every two weeks.
- HF: Labs to be drawn every two weeks.

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)

**→ ALL-WIN ✅**

---
## ROW 20
A/P摘要: "Assessment and Plan    ***** ***** ***** is a 75 y.o. post-menopausal female with \n early stage *****+/*****- IDC of the left breast diagnosed in 20

**Type_of_Cancer**: ⚠️ HF更长(99 vs 68)
- vLLM: ER+/PR+/HER2- grade II invasive ductal carcinoma with 1.8 cm of DCIS
- HF: ER+/PR+/HER2- invasive ductal carcinoma (originally ER+/PR+/HER2-; metastatic biopsy ER+/PR+/HER2-)

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Originally Stage IIA, now metastatic (Stage IV)
- HF: now metastatic (Stage IV)

**Distant Metastasis**: ⚠️ HF更长(25 vs 12)
- vLLM: Yes, to bone
- HF: Yes, to bone, lymph nodes

**response_assessment**: ✅ vLLM更详细
- vLLM: The plan includes repeat imaging after 3 months on treatment to evaluate response.
- HF: Not mentioned in note.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ≈ 相近
- vLLM: Start letrozole, Rx given. Rx for Palbociclib. She will need monthly blood work on Palbociclib. Initiation of denosumab after dental evaluation.
- HF: Start Letrozole, Rx given. Rx for Palbociclib. She will need monthly blood work on Palbociclib. Initiation of denosumab after dental evaluation.

**imaging_plan**: = (完全一致)

**lab_plan**: ≈ 相近
- vLLM: labs including tumor markers. Monthly blood work for Palbociclib monitoring.
- HF: labs including tumor markers. She will need monthly blood work on Palbociclib.

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ≈ 相近
- vLLM: Start Letrozole, Rx given. Rx for Palbociclib. OK to start. Will need monthly blood work on Palbociclib. Initiation of denosumab pending dental clearance.
- HF: Start Letrozole, Rx given. Rx for Palbociclib. OK to start. She will need monthly blood work on Palbociclib. Initiation of denosumab after dental clearance.


---
## ROW 22
A/P摘要: "Assessment / Plan:      1.  Left DCIS in 1994 s/p lumpectomy and radiation. ER positive, no endocrine therapy.   2.  Right stage II IDC in 2000 s/p l

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- invasive ductal carcinoma with metastatic recurrence (bone, chest wall, right infraclavicular and right IM nodes)
- HF: ER+/PR+/HER2- invasive ductal carcinoma (originally ER+/PR+/HER2-; metastatic biopsy ER+/PR-/HER2-)

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: ✅ vLLM更详细
- vLLM: Yes, to bone, chest wall, right infraclavicular and right IM nodes
- HF: Yes, to bones, chest wall

**response_assessment**: ✅ vLLM更详细
- vLLM: PET scans on 11/03/20 and 04/24/21 showed a good response. The patient developed pneumonitis, possibly due to abemaciclib, which was held since 08/14/2021. Physical exam reveals no acute distress, no palpable masses, no skin changes, no lymphadenopathy, and no edema.
- HF: PET/CT scans on 11/03/20 and 04/24/21 showed a good response.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Continue letrozole, abemaciclib. Continue arimidex alone. If PET CT shows progression, could use faslodex with unspecified agent if she has an unspecified mutation. Future options include hormone blockade with Afinitor or Xeloda or a clinical trial.
- HF: If PET CT shows stability, continue arimidex alone. If PET CT shows progression, could use faslodex with [REDACTED] if she has a [REDACTED] mutation. Future options include hormone blockade with afinitor or xeloda or a clinical trial.

**imaging_plan**: ⚠️ HF更长(160 vs 10)
- vLLM: Pet ct now
- HF: I recommend a pet ct now and if stable continue arimidex alone. If pet ct shows progression could use faslodex with [REDACTED] if she has a [REDACTED] mutation.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Continue arimidex alone. If PET CT shows progression, could use Faslodex with unspecified agent if she has an unspecified mutation. Future options include hormone blockade with Afinitor or Xeloda or a clinical trial.; also: letrozole, abemaciclib
- HF: Continue arimidex alone if PET CT is stable. If PET CT shows progression, use faslodex with [REDACTED] if she has a [REDACTED] mutation. Future options include hormone blockade with Afinitor or Xeloda.


---
## ROW 29
A/P摘要: "Assessment and Plan:  ***** *****-***** is a 59 y.o. female with a recently diagnosed multifocal grade 2 invasive ductal carcinoma (ER+/PR+/*****-) w

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- grade 2 invasive ductal carcinoma with mixed micropapillary and ductal features
- HF: ER+/PR+/HER2- invasive ductal carcinoma

**Stage_of_Cancer**: ⚠️ HF更长(30 vs 25)
- vLLM: Stage IIA (pT1c(m)N1(sn))
- HF: pT1c(m)sn, G2, ER+, PR+, HER2-

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ≈ 相近
- vLLM: Continue letrozole. RT planning per [REDACTED], likely pursued locally in [REDACTED].
- HF: Start letrozole 2.5mg PO daily now. Plan to begin radiation therapy locally in [REDACTED].

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Start letrozole 2.5mg PO daily now. Calcium supplementation with 1200mg/day combination of diet and supplement. Vitamin D supplement pending further evaluation. Continue use of vaginal moisturizer. Can also try coconut oil and/or [REDACTED], and will discuss vaginal estrogens at future visit.
- HF: Start letrozole 2.5mg PO daily now. Calcium supplementation with 1200mg/day combination of diet and supplement. Vitamin D supplement pending further evaluation. Continue use of vaginal moisturizer (e.g., [REDACTED]). Can also try coconut oil and/or [REDACTED].


---
## ROW 30
A/P摘要: "Assessment and Recommendations:  64 y.o. postmenopausal patient with a clinical stage II-III *****-/*****+ IDC of the right breast who should proceed

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER-/PR-/HER2+ grade 2 invasive ductal carcinoma with intermediate to high grade DCIS component
- HF: ER-/PR-/HER2+ invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Clinical stage II-III (inferred from large enhancing right breast mass and right axillary lymphadenopathy)
- HF: Stage II-III (inferred from large enhancing right breast mass and right axillary lymph nodes)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: The patient will proceed with neoadjuvant chemotherapy, including either 12 cycles of weekly paclitaxel plus trastuzumab/pertuzumab (THP) followed by 4 cycles of doxorubicin plus cyclophosphamide (AC) every 2 weeks or 6 cycles of every 3 week docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP
- HF: The patient will proceed with neoadjuvant chemotherapy, including either 12 cycles of weekly paclitaxel plus trastuzumab/pertuzumab (THP) followed by 4 cycles of doxorubicin plus cyclophosphamide (AC) every 2 weeks or 6 cycles of every 3 week docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP

**imaging_plan**: ✅ vLLM更详细
- vLLM: The patient will need a TTE prior to starting chemotherapy.
- HF: The patient will need a TTE prior to starting treatment.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)

**→ ALL-WIN ✅**

---
## ROW 33
A/P摘要: "ASSESSMENT & PLAN  Patient Active Problem List   Diagnosis   \u0007 Breast cancer, left breast   \u0007 ***** finger     No problem-specific assessme

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- grade 2 invasive lobular carcinoma
- HF: ER+/PR+/HER2- invasive lobular carcinoma

**Stage_of_Cancer**: ≈ 相近
- vLLM: Originally Stage IIB, now Stage III
- HF: Originally Stage IIB, now Stage IIIA

**Distant Metastasis**: ✅ vLLM独有
- vLLM: Not sure
- HF: (空)

**response_assessment**: ✅ vLLM更详细
- vLLM: No evidence of recurrence on imaging and exam. No palpable masses noted. No significant skin changes. Left neck high <1cm LN soft and mobile, no supraclavicular or axillary lymphadenopathy noted.
- HF: No evidence of recurrence on exam. No specific imaging or lab results mentioned in the current note.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Continue letrozole daily. Encouraged weight bearing exercise. Continue exercise.
- HF: Continue letrozole daily.

**imaging_plan**: ✅ vLLM更详细
- vLLM: Consider MRI brain if [REDACTED] continues.
- HF: If continues, consider MRI brain

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)

**→ ALL-WIN ✅**

---
## ROW 34
A/P摘要: "Assessment:       Stage III breast cancer - *****       Plan:     \n   ***** has had an unfortunate local relapse. This is actually her second local 

**Type_of_Cancer**: ⚠️ HF更长(118 vs 59)
- vLLM: ER+/PR-/HER2- invasive ductal carcinoma with extensive DCIS
- HF: ER+/PR-/HER2- invasive ductal carcinoma (originally ER+/PR low/HER2- in 2011, metastatic biopsy ER+/PR-/HER2- in 2020)

**Stage_of_Cancer**: ⚠️ HF更长(59 vs 9)
- vLLM: Stage III
- HF: Originally Stage III, now local recurrence (not metastatic)

**Distant Metastasis**: ✅ vLLM独有
- vLLM: Not sure
- HF: (空)

**response_assessment**: ✅ vLLM更详细
- vLLM: Local recurrence in left breast with a 1.7cm invasive ductal carcinoma, grade 3, extensive necrosis, skeletal muscle invasion, negative margins. PET-CT shows hypermetabolic tumor at lateral margin of left breast implant, focal uptake without CT lesion in left lateral 6th rib of unclear significance.
- HF: Local recurrence in left breast, 1.7cm IDC on excisional biopsy. No evidence of distant metastasis on imaging (Brain MRI negative, PET-CT shows hypermetabolic tumor at lateral margin of left breast implant, focal uptake without CT lesion in left lateral 6th rib of unclear significance, Breast MRI sh

**current_meds**: = (完全一致)

**goals_of_treatment**: ≈ 相近
- vLLM: curative
- HF: adjuvant

**therapy_plan**: ≈ 相近
- vLLM: Continue radiation therapy referral. Resume hormonal therapy with tamoxifen 20mg PO qD.
- HF: tamoxifen 20mg PO qD, referral to [REDACTED] for chest wall RT, return to clinic in 6 months

**imaging_plan**: = (完全一致)

**lab_plan**: ✅ vLLM独有
- vLLM: check labs
- HF: (空)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)


---
## ROW 36
A/P摘要: "Assessment/Plan    Lab Results   Component Value Date    WBC Count 8.8 04/10/2021    RBC Count 3.91 (L) 04/10/2021    Hemoglobin 11.8 (L) 04/10/2021 

**Type_of_Cancer**: = (完全一致)

**Stage_of_Cancer**: ⚠️ HF更长(33 vs 18)
- vLLM: Stage IIIA (pT3N0)
- HF: Stage IIIA (inferred from pT3 N0)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: No evidence of disease recurrence on imaging and exam. PET/CT on 01/26/21 showed post bilateral mastectomies with associated hypermetabolism along the remaining left breast tissue with drain in place, favored to reflect postprocedural changes and known ongoing infection. Additional low-level hyperme
- HF: Not mentioned in note.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Continue tamoxifen. Continue weekly Abraxane 100mg/m2 x 12 cycles. Continue zoladex for preservation of ovarian reserve during chemotherapy. Referral to radiation oncology, will see Dr. Continue valtrex 1g every day throughout chemo as ppx.; physical therapy
- HF: Continue weekly Abraxane 100mg/m2 x 12 cycles. Continue zoladex for preservation of ovarian reserve during chemotherapy. Continue valtrex 1g every day throughout chemo as ppx.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Continue weekly Abraxane 100mg/m2 x 12 cycles. Continue zoladex for preservation of ovarian reserve during chemotherapy. Continue [REDACTED] as premed. Continue use of antiemetics zofran, compazine, ativan. Continue prilosec. Continue valtrex 1g every day throughout chemo as ppx. Continue lexapro da
- HF: Continue weekly Abraxane 100mg/m2 x 12 cycles. Continue zoladex for preservation of ovarian reserve during chemotherapy. Continue use of antiemetics zofran, compazine, ativan. Continue prilosec. Continue valtrex 1g every day throughout chemo as ppx. Continue lexapro daily. ativan prn. Rx for ambien 


---
## ROW 40
A/P摘要: "ASSESSMENT/PLAN:  ***** ***** ***** is a 62 y.o. female with MS on chronic immunosuppression with newly diagnosed Stage 2 low grade *****+ ***** nega

**Type_of_Cancer**: ⚠️ HF更长(89 vs 73)
- vLLM: ER+/PR-/HER2- grade 1 invasive ductal carcinoma with nuclear grade 1 DCIS
- HF: ER 95, PR 5, HER2 2+ FISH negative (1.2) G1 invasive ductal carcinoma a/w nuclear G1 DCIS

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Stage II (inferred from pT2 N1mi)
- HF: Stage II

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Adjuvant endocrine therapy with letrozole. Continue Prolia for bone protection. No indication for chemotherapy or molecular tests. Patient can start letrozole immediately if no radiation is planned.; physical therapy
- HF: The patient will derive the greatest benefit from adjuvant endocrine therapy with letrozole. She can start letrozole immediately if no radiation is planned. She is currently on Prolia for her osteoporosis.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ≈ 相近
- vLLM: Rx for letrozole given. Continue Prolia.
- HF: Rx for letrozole given. She is on Prolia now.


---
## ROW 41
A/P摘要: "Assessment and Plan:  ***** ***** is a 32 y.o. female ATM mutation carrier with a clinical ***** *****+/PR-/***** negative left breast. Subsequent to

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR weakly+/HER2 1+ by IHC (FISH not available) grade 3 invasive ductal carcinoma
- HF: ER+/PR-/HER2 negative invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM独有
- vLLM: Stage IIIA (inferred from pT2 N2a)
- HF: (空)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: = (完全一致)

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Patient will start with [REDACTED] Taxol for 12 weeks followed by AC. After completion of chemotherapy, ovarian suppression with an aromatase inhibitor will be recommended. Patient may also be eligible for the [REDACTED] trial (with ribociclib).
- HF: After completion of chemotherapy, the patient will be recommended to use an aromatase inhibitor for ovarian suppression. She may also be eligible for a trial with ribociclib.

**→ ALL-WIN ✅**

---
## ROW 42
A/P摘要: "Assessment:       At this time Ms. ***** is and well. She's recently finished her radiation therapy to right breast ***** and is ready to begin her a

**Type_of_Cancer**: ≈ 相近
- vLLM: ER+/PR+/HER2- grade 1 invasive ductal carcinoma
- HF: PR+ invasive ductal carcinoma, HER2: not tested

**Stage_of_Cancer**: ✅ vLLM独有
- vLLM: Stage IA (inferred from pT1 N0)
- HF: (空)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: There is no specific imaging or tumor marker data provided in the note to assess the current response of the cancer. The patient recently completed radiation therapy on January 05 and tolerated it well. The recent physical exam shows the patient is well-developed and well-nourished with normal findi
- HF: On treatment; response assessment not available from current visit.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Continue tamoxifen and return to clinic in 4-6 weeks to assess tolerance.
- HF: Begin a 5 year course of tamoxifen therapy.

**imaging_plan**: ≈ 相近
- vLLM: Routine diagnostic mammogram on the day of the next appointment as her last mammogram on the affected breast was more than 6 months ago.
- HF: Routine diagnostic mammogram on the day of the next appointment, as the last mammogram on the affected breast was more than 6 months ago.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Begin a 5 year course of tamoxifen therapy. Rx for tamoxifen given.
- HF: Begin a 5 year course of tamoxifen therapy.

**→ ALL-WIN ✅**

---
## ROW 44
A/P摘要: "ASSESSMENT & PLAN    ***** ***** is a 33 y.o. female with ER+/PR+/*****- node+ left breast cancer with BRCA1 ***** ***** ***** and  Taxol. She had bi

**Type_of_Cancer**: ⚠️ HF更长(104 vs 66)
- vLLM: ER+/PR+/HER2- grade 2 invasive ductal carcinoma with residual DCIS
- HF: ER+/PR+/HER2- node+ left breast cancer with residual grade 2 invasive ductal carcinoma and residual DCIS

**Stage_of_Cancer**: ✅ vLLM独有
- vLLM: Originally Stage II (inferred from 1 cm residual invasive ductal carcinoma with 14 micrometastatic nodes)
- HF: (空)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: Surgical pathology after bilateral mastectomies with left breast SLN biopsy on 10/07/18 showed 1 cm of residual grade 2 invasive ductal carcinoma (tumor cellularity 15%) with residual DCIS and a 0.07 cm lesion. No evidence of disease recurrence on imaging and exam.
- HF: The patient has residual disease after neoadjuvant therapy and surgery. Surgical pathology showed 1 cm of residual grade 2 invasive ductal carcinoma with residual DCIS and 14/5 nodes with micrometastases. No evidence of recurrence on imaging and exam.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Enrolled on a clinical trial for randomized 3 vs 5 weeks of radiation with tentative start date of 12/16/18. Will start an aromatase inhibitor after completing radiation. May be eligible for the [REDACTED] trial with ribociclib around the time she completes radiation. Submitted authorization for Zol
- HF: She will start an aromatase inhibitor after she completes radiation. She may be eligible for the trial with ribociclib that should open around the time she completes radiation. She will submit authorization for her to get Zoladex in the event that there is a delay in her oophorectomy.

**imaging_plan**: ✅ vLLM更详细
- vLLM: Consider a follow up CT Chest in one year.. PET/CT
- HF: Consider a follow up CT Chest in one year.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: She will start an aromatase inhibitor after completing radiation. She may not require ovarian suppression if she proceeds with bilateral oophorectomy. Authorization will be submitted for Zoladex in case of a delay in oophorectomy.
- HF: Patient will start an aromatase inhibitor after completing radiation. Zoladex will be submitted for authorization in the event of a delay in bilateral oophorectomy.


---
## ROW 46
A/P摘要: "Assessment/Plan     PATHOLOGY:   A. Right breast axillary sentinel lymph nodes:   - 2 lymph nodes involved by metastatic carcinoma (each measuring up

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR-/HER2- grade 1 invasive ductal carcinoma with extensive DCIS
- HF: ER+/PR- HER2- invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Stage IIB (pT2N1(sn) (inferred from 3.5 cm residual disease, 2/2 positive nodes with extranodal extension))
- HF: Stage IIIA (inferred from pT2 N2a)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ≈ 相近
- vLLM: Patient has residual 3.5 cm disease with positive margins after bilateral mastectomies. Pathology shows 2/2 positive nodes with extranodal extension. Imaging findings include: hypermetabolic right breast mass consistent with known invasive ductal carcinoma, associated hypermetabolic right axillary, 
- HF: The cancer is currently responding to treatment. The patient has a 3.5 cm residual disease in the right breast with positive margins and 2/2 positive sentinel lymph nodes with extranodal extension. The surgical pathology after neoadjuvant therapy shows a residual tumor with a probable or definite re

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Patient will start letrozole now. Addition of abemaciclib discussed after completion of radiation therapy. Continuing exercise.
- HF: The patient will start letrozole now. Discussed addition of abemaciclib after completion of xrt.

**imaging_plan**: ≈ 相近
- vLLM: MRA of the abdomen in 1 year, due in January 2022.. DEXA scan
- HF: Baseline dexa ordered. MRA of the abdomen due in January 2022.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ⚠️ HF更长(259 vs 182)
- vLLM: Will start letrozole now. Rx sent. Continue naproxen 500mg bid, APAP ok if taken sparingly. Discussed tramadol if pain worsens/uncontrolled. Continue allegra daily. Continue PO iron.
- HF: Start letrozole now. Continue naproxen 500mg bid, APAP ok if taken sparingly. Discussed tramadol if pain worsens/uncontrolled. Continue allegra daily. Continue PO iron. Continue gabapentin but pt did not tolerate stopping this med so does not wish to restart.


---
## ROW 49
A/P摘要: "Impression/Plan: 50 y.o. female with new diagnosis of L breast cancer with biopsy-proven nodal \n disease at diagnosis. PET-CT done, MRI BL breasts d

**Type_of_Cancer**: = (完全一致)

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Likely stage 2 (inferred from primary tumor size and nodal involvement)
- HF: Likely stage 2

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: = (完全一致)

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: The current plan for adjuvant endocrine therapy is subject to change based on the results of the surgery and lymph node evaluation. There is a plan to put the patient on tamoxifen, but this is contingent upon obtaining more records to assess the patient's personal risk of thrombophilia.
- HF: Patient to be put on tamoxifen, with a request to obtain more records to assess the patient's personal risk of thrombophilia. No specific doses or frequencies mentioned.

**→ ALL-WIN ✅**

---
## ROW 50
A/P摘要: "Assessment / Plan:    1.  De ***** metastatic breast cancer found in July 2013, HR+ and her 2 neu negative.  S/p ***** x 4 then tamoxifen lupron unti

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: HR+ and HER2- metastatic breast cancer with IDC and DCIS components
- HF: ER+/PR+/HER2- invasive ductal carcinoma (IDC) and DCIS

**Stage_of_Cancer**: ⚠️ HF更长(59 vs 32)
- vLLM: Originally Stage IV (T2, N1, M1)
- HF: Originally Stage IV (T2, N1, M1), now metastatic (Stage IV)

**Distant Metastasis**: ⚠️ HF更长(46 vs 29)
- vLLM: Yes, to lung, liver, and bone
- HF: Yes, to the lung, lymph nodes, liver, and bone

**response_assessment**: ✅ vLLM更详细
- vLLM: Imaging from December 2021 shows metastatic disease under good control. The patient remains on ibrance, xgeva, letrozole and lupron.
- HF: Imaging from December 2021 shows metastatic disease under good control.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: = (完全一致)

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ⚠️ HF更长(232 vs 50)
- vLLM: Lupron, letrozole, and ibrance added January 2015.
- HF: Current medications include tamoxifen, lupron, letrozole, and ibrance. No specific future medication plans, changes to current medications, supportive medications, bowel regimen, or blood transfusion plans are mentioned in the note.


---
## ROW 52
A/P摘要: "Assessment/Plan and in my HPI/Oncologic History    Results for orders placed or performed during the hospital encounter of 12/04/20   POCT Urine Preg

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- grade II invasive ductal carcinoma
- HF: ER+/PR+/HER2- invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Stage IIA (inferred from pT2 N1mi)
- HF: Stage II/III

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Continue radiation therapy referral. [REDACTED] send Zoladex prior auth.
- HF: [REDACTED] send Zoladex prior auth.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ≈ 相近
- vLLM: Order [REDACTED] to provide more information on her tumor biology and likelihood of benefit from chemotherapy.
- HF: Order an [REDACTED] to provide more information on her tumor biology and likelihood of benefit from chemotherapy.

**medication_plan**: = (完全一致)

**→ ALL-WIN ✅**

---
## ROW 53
A/P摘要: "Assessment:       Stage II/III left breast cancer, ER/PR positive, ***** positive, s/p left lumpectomy/*****      Plan:       Status of disease and \

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2+ invasive ductal carcinoma with neuroendocrine differentiation, grade 3, with high-grade DCIS component
- HF: ER+/PR+/HER2+ invasive ductal carcinoma with neuroendocrine differentiation

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ≈ 相近
- vLLM: Adjuvant systemic chemotherapy with AC x 4 given q2weeks with growth factor support, followed by 12 weeks of taxol along with one year of trastuzumab and pertuzumab. Alternative TCHP regimen consisting of 6 cycles of TCHP with one year of trastuzumab/pertuzumab. Extended adjuvant neratinib in year 2
- HF: Adjuvant AC/THP chemotherapy consisting of AC x 4 given q2weeks with growth factor support, followed by 12 weeks of taxol along with one year of trastuzumab and pertuzumab. Alternative TCHP regimen consists of 6 cycles of TCHP with one year of trastuzumab/pertuzumab. Adjuvant hormone therapy with Ar

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ⚠️ HF更长(64 vs 54)
- vLLM: Referral to genetic counseling for further evaluation.
- HF: Offered a referral to genetic counseling for further evaluation.

**medication_plan**: ✅ vLLM更详细
- vLLM: Adjuvant AC/THP chemotherapy consisting of AC x 4 given q2weeks with growth factor support, followed by 12 weeks of taxol along with one year of trastuzumab and pertuzumab. Alternative TCHP regimen consists of 6 cycles of TCHP with one year of trastuzumab/pertuzumab. Adjuvant hormone therapy recomme
- HF: Adjuvant AC/THP chemotherapy: AC x 4 given q2weeks with growth factor support, followed by 12 weeks of taxol along with one year of trastuzumab and pertuzumab. Alternative TCHP regimen: 6 cycles of TCHP with one year of trastuzumab/pertuzumab. Extended adjuvant neratinib in year 2 with potential for


---
## ROW 54
A/P摘要: "Assessment and Recommendations:  39 y.o. premenopausal patient with a recent diagnosis of a deleterious BRCA2 mutation and a oligometastatic *****+/*

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- grade 1 invasive ductal carcinoma with extensive DCIS component
- HF: ER+/PR+/HER2- invasive ductal carcinoma

**Stage_of_Cancer**: ⚠️ HF更长(25 vs 21)
- vLLM: Stage IV (metastatic)
- HF: now metastatic (Stage IV)

**Distant Metastasis**: ≈ 相近
- vLLM: Yes, to left posterior 7th rib and T6 vertebral body
- HF: Yes, to bone (left posterior 7th rib and T6 vertebral body)

**response_assessment**: ✅ vLLM更详细
- vLLM: The cancer is currently responding with stable disease. Evidence includes stable soft tissue density labeling pattern of the left breast on PET/CT performed on 01/29/18. Additionally, the left posterior T6 vertebral body lesion (1.1 cm) is consistent with treated metastatic disease, showing no suspi
- HF: Surgical pathology after neoadjuvant therapy shows 8.2 cm residual grade 1 IDC with cellularity of ~10%, ER+ 50%, HER2- (IHC 2; FISH ratio 1.4), and Ki-67 1%; margins negative and no lymphovascular invasion; 7 cm of residual high nuclear grade DCIS with treatment effect present; March 24 SLN+ (0.15 

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: continue leuprolide every 4 weeks, continue letrozole, referred to radiation oncology for post-mastectomy radiation, start palbociclib after radiation, continue zoledronic acid every 3 months, take calcium 1250 mg daily, take vitamin D 1000 to 2000 units daily, perform weight-bearing exercise.
- HF: continue leuprolide every 4 weeks, continue letrozole, referred to radiation oncology for post-mastectomy radiation, start palbociclib after radiation, zoledronic acid every 3 months, calcium 1250 mg daily, vitamin D 1000 to 2000 units daily

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ≈ 相近
- vLLM: continue leuprolide every 4 weeks, continue letrozole, start palbociclib after radiation, zoledronic acid every 3 months, calcium 1250 mg daily, vitamin D 1000 to 2000 units daily
- HF: Continue leuprolide every 4 weeks, continue letrozole, start palbociclib after radiation, continue zoledronic acid every 3 months, take calcium 1250 mg daily, take vitamin D 1000 to 2000 units daily.


---
## ROW 57
A/P摘要: "IMP  1. Breast CA, Left sided, locally advanced. Initially classified as ***** at ***** hospital, and treated with TCH+P based on ***** neoadjuvant t

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: Breast Cancer (TNBC), originally classified as Grade III adenocarcinoma, ER+/PR+/HER2-
- HF: ER-/PR-/HER2- breast cancer, triple negative

**Stage_of_Cancer**: ⚠️ HF更长(106 vs 84)
- vLLM: Locally advanced (inferred from treatment with neoadjuvant chemotherapy and surgery)
- HF: Locally advanced (inferred from description of residual tumor and treatment with neoadjuvant chemotherapy)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: The patient received neoadjuvant chemotherapy with TCH+P followed by surgery on 12/25/2013. Pathology showed residual tumor of 3.7 cm with 0/6 nodes positive, indicating that the cancer did not achieve a pathologic complete response (pCR). No specific imaging or lab measurements are provided to deta
- HF: The patient received neoadjuvant chemotherapy with TCH+P, followed by surgery which showed a residual tumor of 3.7 cm with 0/6 nodes positive. Post-surgery, the patient received AC x 4 cycles. The physical exam shows the healing left mastectomy site with mild tenderness, no drainage, and no palpable

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: = (完全一致)

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM独有
- vLLM: Recommendation to resume trastuzumab if [REDACTED] status is confirmed. Radiation therapy (XRT) scheduled.
- HF: (空)


---
## ROW 59
A/P摘要: "ASSESSMENT & PLAN  ***** ***** is a 52 y.o. female  with stage 1 right sided ER+/PR+/*****- breast cancer in September 2016 which was ***** occult. S

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- grade 3 invasive ductal carcinoma with high-grade DCIS component
- HF: ER+/PR+/HER2- invasive ductal carcinoma, high grade DCIS

**Stage_of_Cancer**: ⚠️ HF更长(105 vs 32)
- vLLM: Stage IIA (inferred from pT2 N0)
- HF: Not explicitly stated, inferred as Stage I (T1-2 N0 M0 based on negative nodes and no distant metastasis)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ⚠️ HF更长(486 vs 291)
- vLLM: No evidence of recurrence either locally or systemically based on physical exam findings or review of symptoms. Physical exam shows a well-healed lumpectomy scar with no dominant mass in either breast. No palpable lymphadenopathy, no hepatosplenomegaly, and no suspicious skin lesions noted.
- HF: Patient is currently without evidence of recurrence either locally or systemically based on physical exam findings or review of symptoms. Lumpectomy scar is well healed with no dominant mass in either breast. No palpable lymphadenopathy, no hepatosplenomegaly, no wheezes, symmetric air entry, normal

**current_meds**: ✅ vLLM更详细
- vLLM: "exemestane ([REDACTED]) 25 mg tablet", "letrozole (FEMARA) 2.5 mg tablet"
- HF: exemestane ([REDACTED])

**goals_of_treatment**: = (完全一致)

**therapy_plan**: = (完全一致)

**imaging_plan**: ≈ 相近
- vLLM: Right mammogram due in July. Continue mammograms alternating with MRI and every 6 month clinical breast exam.
- HF: Right mammogram due in July, continue mammograms alternating with MRI, and every 6 month clinical breast exam.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Discontinue Letrozole and wait 2-3 weeks before starting Exemestane. Continue Pristiq 75 mg. Refer to psychiatry to determine how to proceed with a transition from current antidepressant to Duloxetine. Discuss potential side effects of Duloxetine including fatigue, nausea, headache, and dry mouth.
- HF: Discontinue Letrozole and wait 2-3 weeks before starting Exemestane. Continue Pristiq 75 mg. Consider transitioning to Duloxetine for joint pain, but will refer to psychiatry to determine the best course of action due to potential drug interactions.


---
## ROW 61
A/P摘要: "Assessment and Plan     # Breast CA L    ***** ***** is a 43 y.o. pre-menopausal female newly diagnosed left breast IDC ER+PR+*****- found on routine

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- (1+) grade 2 invasive ductal carcinoma
- HF: ER+/PR+/HER2- (1+) invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM独有
- vLLM: Stage I (inferred from tumor ≤2cm)
- HF: (空)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Will likely need [unspecified agent] Dx after surgery to determine if she needs adjuvant chemotherapy. She will need adjuvant endocrine therapy (Tamoxifen vs Ovarian Suppression + [unspecified agent]).; physical therapy
- HF: Will likely need [REDACTED] Dx after surgery to determine if she needs adjuvant chemotherapy. She will need adjuvant endocrine therapy (Tamoxifen vs Ovarian Suppression + [REDACTED]).

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ✅ vLLM独有
- vLLM: will likely need [REDACTED] Dx after surgery to determine if she needs adjuvant chemotherapy
- HF: (空)

**medication_plan**: ≈ 相近
- vLLM: she will need adjuvant endocrine therapy (Tamoxifen vs Ovarian Suppression + [REDACTED])
- HF: Patient will need adjuvant endocrine therapy with either Tamoxifen or Ovarian Suppression + [REDACTED].

**→ ALL-WIN ✅**

---
## ROW 64
A/P摘要: "Assessment / Plan:    1. Stage III- IV left breast cancer HR+/her 2 negative with probably metastatic disease to the sternum.   2.  She is currently 

**Type_of_Cancer**: ≈ 相近
- vLLM: HR+/HER2- invasive ductal carcinoma
- HF: ER+/PR+/HER2- invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Stage IV (metastatic)
- HF: Stage IV- IV

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: No specific imaging or tumor marker evidence provided in the note to assess the current response to treatment.
- HF: Not yet on treatment — no response to assess.

**current_meds**: = (完全一致)

**goals_of_treatment**: ✅ vLLM更详细
- vLLM: palliative
- HF: curative

**therapy_plan**: ⚠️ HF更长(235 vs 184)
- vLLM: Recommend [REDACTED] followed by taxol then surgery and radiation with additional treatment to sternum as a single site of metastatic disease. If biopsy of bone is positive, add xgeva.
- HF: Currently on [REDACTED] and taxol planned. Recommended [REDACTED] followed by taxol then surgery and radiation with additional treatment to sternum as a single site of metastatic disease. If biopsy of bone is positive, would add xgeva.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ✅ vLLM独有
- vLLM: No specific genetic or molecular tests are planned.
- HF: (空)

**medication_plan**: ✅ vLLM更详细
- vLLM: Currently on unspecified agent and taxol planned. If biopsy of bone is positive, will add xgeva.
- HF: [REDACTED] and taxol planned.


---
## ROW 65
A/P摘要: "ASSESSMENT/PLAN:  ***** ***** is a 48 y.o. female with a recent diagnosis of right breast IDC which is ER weak positive (2%), PR low positive (7%), *

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER weak positive (2%), PR low positive (7%), HER2 neg (IHC 2+, FISH 2.March 09.8=1.4) grade 2 or 3 invasive ductal carcinoma with high-grade DCIS component
- HF: ER weak positive (2%), PR low positive (7%), HER2 neg (IHC 2+, FISH 2.March 09.8=1.4) invasive ductal carcinoma with high-grade DCIS component

**Stage_of_Cancer**: ⚠️ HF更长(106 vs 53)
- vLLM: Stage IB (corrected: pT1 N1mi — micrometastasis only)
- HF: Stage II (inferred from pT2 N1 with 0.2mm focus of micrometastatic carcinoma within the lymph node tissue)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ≈ 相近
- vLLM: Continue taxol. Port placement, chemotherapy teaching session, interested in screening for ISPY trial; After surgery, consider for post operative radiation and recommend 5-10 years of adjuvant endocrine therapy. RTC in 1-2 weeks in person to start chemo.
- HF: Port placement, chemotherapy teaching session, will start neoadjuvant chemotherapy with options including AC/T or ISPY clinical trial enrollment. After surgery, she will be considered for post-operative radiation and 5-10 years of adjuvant endocrine therapy.

**imaging_plan**: ✅ vLLM更详细
- vLLM: research breast MRI
- HF: Order TTE

**lab_plan**: ⚠️ HF更长(18 vs 4)
- vLLM: labs
- HF: labs. F/u pending.

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ⚠️ HF更长(430 vs 352)
- vLLM: Plan to start neoadjuvant chemotherapy with AC/T. Typically, taxol first, followed by four cycles of TC. Option to enroll in ISPY clinical trial with various regimens including Taxol weekly for 12 weeks followed by AC every three weeks for 4 cycles, or other experimental regimens. Post-surgery, will
- HF: Neoadjuvant chemotherapy with options including AC/T (doxorubicin and cyclophosphamide followed by paclitaxel) or enrollment in the ISPY clinical trial with various regimens such as Taxol weekly for 12 weeks followed by AC every three weeks for 4 cycles, or Taxol with pembrolizumab, olaparib, durval


---
## ROW 68
A/P摘要: "ASSESSMENT & PLAN  ***** ***** is a 63 y.o. postmenopausal female who presents  to clinic for consultation of her breast cancer and the following spe

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2+ multifocal invasive ductal carcinoma
- HF: ER+/PR+/HER2+ multifocal breast cancer

**Stage_of_Cancer**: ⚠️ HF更长(73 vs 34)
- vLLM: Stage I (inferred from tumor ≤2cm)
- HF: Early stage (inferred from multifocal disease with no distant metastasis)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: The cancer has shown a good clinical response after 6 cycles of TCHP chemotherapy, as evidenced by the follow-up MRI showing no lesions after chemotherapy. Additionally, the physical exam did not reveal any palpable lesions, indicating a favorable response to the treatment regimen.
- HF: The cancer is currently responding to treatment. Follow-up MRI shows no lesions after chemotherapy, indicating a clinical response to the 6 cycles of TCHP.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: If a lumpectomy is chosen, radiation is required. Post-mastectomy radiation may be considered if there is extensive disease and lymph node involvement. The importance of diet and exercise regarding breast cancer outcome was re-emphasized. The patient was counseled on the risk of recurrence, treatmen
- HF: If she chooses to have a lumpectomy, she should have radiation. Post-mastectomy radiation would be considered if there is extensive disease left and lymph nodes are involved.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ⚠️ HF更长(147 vs 107)
- vLLM: Her sons should be tested for the risk of [REDACTED] anemia in children and the risk for pancreatic cancer.
- HF: Her sons should be tested for the risk of [REDACTED] anemia in children (if the spouse also carries a mutation) and the risk for pancreatic cancer.

**medication_plan**: ⚠️ HF更长(150 vs 73)
- vLLM: No specific current or future medication plans were detailed in the note.
- HF: No specific future medication plans, changes to current medications, supportive medications, bowel regimen, or blood transfusion plans were mentioned.


---
## ROW 70
A/P摘要: "Assessment \\Plan :    1.   Bilateral ER positive and her 2 negative breast cancer s/p neoadjuvant TC x 6 cycles due to high risk ***** on the left s

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- grade 2 invasive lobular carcinoma with 1 lymph node positive (left side); ER+/PR-/HER2- grade 2 invasive ductal carcinoma with DCIS (right side)
- HF: ER+/PR+/HER2- invasive lobular carcinoma (left breast); ER+/PR-/HER2- invasive ductal carcinoma (right breast)

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Originally Stage II (inferred from pT4N1 on left side and pT1N0 on right side), now post-neoadjuvant therapy
- HF: (inferred from pT4 N1 on left side, pT1 N0 on right side), now post-neoadjuvant therapy

**Distant Metastasis**: = (完全一致)

**response_assessment**: ⚠️ HF更长(393 vs 258)
- vLLM: MRI shows faint residual non-mass enhancement in both breasts, with decreased size and normal morphology of left axillary nodes. Bone scan showed no definite scintigraphic evidence of osseous metastases. No evidence of disease recurrence on imaging and exam.
- HF: The cancer is currently responding to treatment as evidenced by the MRI showing faint residual non-mass enhancement in both breasts, with left axillary nodes having decreased in size and now have normal size/morphology. Additionally, the bone scan shows no definite scintigraphic evidence of osseous 

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(166 vs 111)
- vLLM: Restart letrozole which she had previously tolerated. She is going to have expanders placed prior to radiation.
- HF: She is going to have expanders placed prior to radiation. She will also undergo radiation therapy and has a follow-up CT scan for lung nodules scheduled in June 2020.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ⚠️ HF更长(108 vs 62)
- vLLM: She will restart letrozole which she had previously tolerated.
- HF: Restart letrozole which she had previously tolerated. Information about [REDACTED] to help with hot flashes.


---
## ROW 72
A/P摘要: "Assessment/Plan    Results for orders placed or performed during the hospital encounter of 03/03/22   *****-19 RNA, RT-PCR/Nucleic Acid Amplification

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR-/HER2- grade 2 invasive ductal carcinoma with focal neuroendocrine differentiation
- HF: ER+/PR-/HER2- invasive ductal carcinoma with focal neuroendocrine differentiation

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Stage IA (pT1cN0(sn))
- HF: pT1cN0(sn)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(126 vs 85)
- vLLM: Continue letrozole. Ordered [REDACTED] to evaluate potential benefit of chemotherapy.
- HF: Instructed patient to begin letrozole, prescription ordered. Ordered [REDACTED] to evaluate potential benefit of chemotherapy.

**imaging_plan**: ✅ vLLM独有
- vLLM: Ultrasound
- HF: (空)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: = (完全一致)


---
## ROW 78
A/P摘要: "ASSESSMENT/PLAN:  ***** ***** is a 79 \n y.o. female  with MMM including DM, HTN hyperlipidemia, h/o hemorrhagic L brainstem CVA February 13 cavernou

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER-/PR-/HER2- grade 3 invasive ductal carcinoma
- HF: ER-/PR-/HER2- triple negative breast cancer

**Stage_of_Cancer**: ≈ 相近
- vLLM: Metastatic (Stage IV)
- HF: Stage IV (metastatic)

**Distant Metastasis**: ✅ vLLM更详细
- vLLM: Yes, to liver and periportal lymph nodes
- HF: Yes, to liver and periportal LNs

**response_assessment**: ⚠️ HF更长(622 vs 522)
- vLLM: Worsening of metastatic disease noted on 08/07/19 Abdominal CT showing interval enlargement of hepatic and nodal metastases. Specifically, a 2 cm hypodense lesion in segment 7 of the liver, which previously measured 1.3 cm, and a 2.9 x 2.4 cm portocaval lymph node, which previously measured 1.7 cm, 
- HF: Worsening of metastatic disease with interval enlargement of hepatic and nodal metastases. CT abdomen/pelvis on 08/07/19 shows a 2 cm hypodense lesion in segment 7 of the liver, which has progressively enlarged from 1.3 cm. An additional 2 x 1.7 cm hypodense lesion in segment 7 also shows significan

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: She is interested in screening for a trial at [REDACTED] involving [REDACTED]+pembrolizumab or a phase 3 trial of [REDACTED] with Eribulin vs eribulin alone. She is not interested in chemotherapy at this time and prefers to explore the [REDACTED] trial at [REDACTED]. She has a consultation with radi
- HF: She is interested in screening for a trial at [REDACTED] including phase 1 [REDACTED]+pembrolizumab and phase 3 trial of [REDACTED] with Eribulin vs eribulin alone. She is not interested in chemotherapy at this time and would like to explore the [REDACTED] trial at [REDACTED].

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ⚠️ HF更长(122 vs 97)
- vLLM: Patient is interested in screening for the [REDACTED] trial at [REDACTED] for [REDACTED]+ tumors.
- HF: Patient is interested in screening for the [REDACTED] trial at [REDACTED], which may involve genetic or molecular testing.

**medication_plan**: = (完全一致)


---
## ROW 80
A/P摘要: "Assessment and Plan:  Patient Active Problem List   Diagnosis   \u0007 Breast cancer, left breast (HCC)       IMP  ***** ***** ***** is a 53 y.o. fem

**Type_of_Cancer**: ≈ 相近
- vLLM: ER+/PR+/HER2- grade 3 invasive ductal carcinoma
- HF: ER+/PR+ invasive ductal carcinoma, HER2: not tested

**Stage_of_Cancer**: ✅ vLLM独有
- vLLM: Stage I (inferred from tumor ≤2cm)
- HF: (空)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(128 vs 87)
- vLLM: Start TC x 4 on 04/11/19, with [REDACTED]. RTC cycle 2 to see me, call with any issues.
- HF: Start TC x 4 on 04/11/19, with 6 weeks of radiation therapy, 5 weeks with a one week boost, including left axilla and SC fields.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ✅ vLLM独有
- vLLM: Whole genome sequencing was completed and there are no actionable mutations. No further genetic testing is planned.
- HF: (空)

**medication_plan**: ≈ 相近
- vLLM: Start TC x 4 on 04/11/19, with [REDACTED]. Claritin for 5-6 days. Pain medications for cold cap discussed. Cold gloves to be used.
- HF: Start TC x 4 on 04/11/19, with Claritin for 5-6 days. Discussed pain medications for cold cap and cold gloves for neuropathy and fingernails.


---
## ROW 82
A/P摘要: "Assessment & Plan:   Has excellent grief counselor and continues to meet weekly. Holidays went well spending time with son and other family distantly

**Type_of_Cancer**: = (完全一致)

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: We discussed the role of chemotherapy to decrease the risk of systemic recurrence. Due to her low risk, I do not recommend chemotherapy. We discussed the role of radiation to decrease the risk of local recurrence. RTC after radiation. Plan to proceed with [REDACTED] +/- bone medication after radiati
- HF: We discussed the role of chemotherapy to decrease the risk of systemic recurrence. Due to her low risk, I do not recommend chemotherapy. We discussed the role of radiation to decrease the risk of local recurrence. Plan to proceed with [REDACTED] +/- bone medication after radiation is completed.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ⚠️ HF更长(356 vs 169)
- vLLM: Continue hydrochlorothiazide 12.5 mg tablet daily before lunch. Continue lisinopril 40 mg tablet daily before lunch. Continue metformin 500 mg tablet daily before lunch.
- HF: Continue current medications including acetaminophen 1000 mg by mouth every 8 hours, ibuprofen 600 mg by mouth every 8 hours as needed for pain or temperature, hydrochlorothiazide 12.5 mg by mouth daily before lunch, lisinopril 40 mg by mouth daily before lunch, metformin 500 mg by mouth daily befor


---
## ROW 84
A/P摘要: "ASSESSMENT/PLAN:   ***** ***** is a 60 y.o. female with a CHEK2 mutation, multiple sclerosis, and metastatic breast cancer with disease in bone, soft

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- grade 2 invasive ductal carcinoma with metastatic recurrence to bone, soft tissue, liver, and possibly meninges
- HF: ER+/PR- (71-80%, <1%) invasive ductal carcinoma, HER2 equivocal

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ⚠️ HF更长(913 vs 699)
- vLLM: MRI brain with contrast on 11/07/2020 showed diffuse irregular enhancement along the bilateral cerebral convexities and right petroclival region, with increased involvement of the right internal auditory canal compared to 09/29/2020. There were no active lesions, and stable demyelinating disease was
- HF: The cancer is currently stable on imaging and exam. MRI brain with contrast on 11/07/2020 showed diffuse irregular enhancement along the bilateral cerebral convexities and right petroclival region, with increased involvement of the right internal auditory canal compared to 09/29/2020. However, there

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(492 vs 273)
- vLLM: refer to radiation oncology for consideration of radiation therapy (either focal CNS radiation or larger portion); continue Xeloda 1500mg BID for now; at time of progression, could consider fulvestrant + CDK4/6 inhibitor given the CHEK2 mutation; continue zolendronic acid.
- HF: Repeat CT CAP now, Repeat LP for CSF cytology, Repeat MRI spine to rule out LMD in the spine, Recommend referral to radiation oncology to consider either focal CNS radiation or possible even [REDACTED], Could consider starting low dose steroids to see if reduction of swelling improves any of her sym

**imaging_plan**: ✅ vLLM更详细
- vLLM: Repeat CT CAP now, Repeat MRI spine to rule out leptomeningeal disease in the spine
- HF: Repeat CT CAP now, Repeat MRI spine to r/o LMD in the spine

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Continue xeloda 1500mg BID for now, continue zolendronic acid, could consider starting low dose steroids to see if reduction of swelling improves any of her symptoms, at time of progression of disease, could consider fulvestrant + [REDACTED] given the [REDACTED] mutation on STRATA testing; also: let
- HF: Continue xeloda 1500mg BID for now, could consider starting low dose steroids, continue zolendronic acid


---
## ROW 85
A/P摘要: "ASSESSMENT/PLAN:  ***** ***** is a 61 y.o. female with a h/o clinical stage *****, ***** stage IIIA ER+ invasive lobular carcinoma of the right breas

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR-/HER2- invasive lobular carcinoma with pleomorphic features, multifocal, overall grade 3
- HF: ER+/PR-/HER2- invasive lobular carcinoma

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: ≈ 相近
- vLLM: Yes, to bone, liver, and brain
- HF: Yes, to bone, muscle, and brain

**response_assessment**: ⚠️ HF更长(440 vs 356)
- vLLM: The cancer is currently progressing on first line fulvestrant/palbociclib, as evidenced by new liver metastases and increased bony disease on PET CT (non-con) on 04/11/2018. Additionally, there is an unchanged 6 mm enhancing lesion in the left occipital lobe and leptomeningeal disease involving the 
- HF: Disease progressed on first line fulvestrant/palbociclib in bone with new liver metastases. Brain MRI reviewed by UCSF neuroradiology and found to have an enhancing lesion in [REDACTED]'s [REDACTED] involving left trigeminal nerve, concerning for metastatic disease with a leptomeningeal component. T

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(163 vs 133)
- vLLM: Metastatic breast cancer patient will be evaluated for a phase 1 trial of [REDACTED]+olaparib for patients with [REDACTED] mutations.
- HF: The patient will be evaluated for a phase 1 trial of [REDACTED]+olaparib for patients with [REDACTED] mutations. There is a 2-week radiation washout for the trial.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ⚠️ HF更长(128 vs 108)
- vLLM: Patient will be evaluated for a phase 1 trial of [REDACTED]+olaparib for patients with [REDACTED] mutations.
- HF: She will be evaluated today by Dr. [REDACTED] for a phase 1 trial of [REDACTED]+olaparib for patients with [REDACTED] mutations.

**medication_plan**: = (完全一致)


---
## ROW 87
A/P摘要: "Assessment:       Ms. ***** is a 79-year-old woman with a 2.2 cm multifocal tumor in the right breast which was resected with clear margins.  There w

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- grade 2 invasive ductal carcinoma with a separate focus of well-differentiated adenocarcinoma
- HF: ER+/PR+/HER2- invasive ductal carcinoma

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(133 vs 59)
- vLLM: [REDACTED] will receive a course of hormonal therapy alone.
- HF: [REDACTED] will receive a course of hormonal therapy alone. The specific hormonal therapy and schedule were not detailed in the note.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Ms. [REDACTED] will prefer to receive a course of hormonal therapy alone. Specific agents and dosages were not detailed in the note.
- HF: Ms. [REDACTED] will receive a course of hormonal therapy alone. Specific drug names, doses, and frequencies were not provided.


---
## ROW 88
A/P摘要: "Assessment / Plan:    1.  Stage III left sided breast cancer s/p neoadjuvant AC followed by Taxol then taxol carbo, stopped for progression of diseas

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: Invasive ductal carcinoma, ER weak+, PR-, HER2- with metastatic recurrence to brain
- HF: ER+/PR+/HER2- invasive ductal carcinoma, metastatic biopsy ER-/PR-/HER2-

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ⚠️ HF更长(184 vs 103)
- vLLM: She is on xeloda and I would recommend restaging after 3 months of therapy is she is stable clinically.
- HF: No new imaging findings are reported in this visit, and the patient has no palpable masses, skin changes, or lymphadenopathy on physical exam. The current assessment is stable disease.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(237 vs 137)
- vLLM: Continue xeloda. Discuss clinical trials using immunotherapy or using immunotherapy with chemotherapy off trial if progression on xeloda.
- HF: She is on xeloda and I would recommend restaging after 3 months of therapy is she is stable clinically. We discussed clinical trials using immunotherapy or using immunotherapy with chemotherapy off trial if she has progression on xeloda.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ⚠️ HF更长(297 vs 218)
- vLLM: She is on xeloda. If progression on xeloda occurs, clinical trials using immunotherapy or immunotherapy with chemotherapy off trial may be considered. If HER2+ disease is identified, anti-HER2 therapy will be required.
- HF: She is on xeloda. If she has HER2 positive disease, she will need anti-HER2 therapy. Restaging after 3 months of therapy if she is stable clinically. If she has progression on xeloda, she may be considered for clinical trials using immunotherapy or using immunotherapy with chemotherapy off trial.


---
## ROW 90
A/P摘要: "# Breast CA, R Presented with palpable lesion. Clinical st II/III. Approx 3 cm tumor on initial imaging. ***** *****. ***** High Risk. s/p Taxol, wit

**Type_of_Cancer**: ⚠️ HF更长(90 vs 36)
- vLLM: Adenocarcinoma of right breast (HCC)
- HF: Adenocarcinoma of right breast (HCC) - ER/PR/HER2 status not explicitly stated in the note

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ≈ 相近
- vLLM: Physical exam via video observation shows slight tissue swelling in the axilla without erythema or drainage, palpitations with port site tenderness, constipation, mild nausea, and headaches. Thyroid stimulating hormone elevated at 6.01 mIU/L, indicating possible hypothyroidism. Elevated alkaline pho
- HF: Pathology from initial imaging showed a 3 cm tumor. After treatment, residual IDC of 2.2 cm with approximately 60% cellularity was noted. Physical exam via video observation shows slight tissue swelling in the axilla, no erythema or drainage, palpitations, and port site tenderness. Gastrointestinal 

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: continue with cycle 4 of AC in 1 week (dose delay x 1 wk) to facilitate recovery from sx's - reduce GCSF dose to 50%. RTC after XRT, approx 1-1.5 mos.
- HF: Continue with cycle 4 of AC in 1 week (dose delay x 1 wk) to facilitate recovery from sx's.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Continue with cycle 4 of AC in 1 week (dose delay x 1 wk). Reduce GCSF dose to 50%. Add granisetron for N/V. Add PO dex at home prn N/V. Add olanzapine 10 mg prn N/V. Continue lidocaine patches and analgesics prn. Continue gabapentin.
- HF: Continue cycle 4 of AC in 1 week, reduce GCSF dose to 50%. Add PO dex at home prn N/V, add olanzapine 10 mg prn N/V. Try granisetron for N/V.


---
## ROW 91
A/P摘要: "ASSESSMENT & PLAN  Breast cancer, stage 4  ***** ***** *****, ***** ***** ***** and exemestane daily since April 2012. RLE edema improved, weight dow

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+ invasive ductal carcinoma with metastatic recurrence to bone, HER2: not tested
- HF: ER+/PR+ invasive ductal carcinoma, HER2: not tested

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: MRI pelvis on 11/08/2011 shows moderate increase in size and extent of right iliac lesion abutting the right acetabular articular surface and extending along the right pubic root, with multiple new suspicious T2 hyperintense/T1 hypointense lesions within the sacrum, left ischial tuberosity, and left
- HF: MRI pelvis and PET/CT scans show an increase in bone metastases and new suspicious lesions, indicating that the cancer is not responding to the current treatment with everolimus, exemestane, and denosumab.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ⚠️ HF更长(298 vs 92)
- vLLM: Continue exemestane daily. Continue denosumab for hip pain.; lasix, KCL, elevation for edema
- HF: Continue exemestane daily, continue [REDACTED] [REDACTED] and elevation for leg edema, continue lasix 10mg daily with KCL 10Meq daily, continue denosumab for hip pain, PET/CT next week to evaluate disease burden, labs monthly, RTC in 1 month, topical antifungal 2 times daily for fungal dermatitis.

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Continue lasix 10mg daily with KCL 10Meq daily, continue denosumab, topical antifungal 2 times daily; also: exemestane
- HF: Continue lasix 10mg daily with KCL 10Meq daily, continue denosumab, topical antifungal 2 times daily


---
## ROW 92
A/P摘要: "ASSESSMENT & PLAN  Breast cancer metastasized to multiple sites  Plan cycle#2 D1 Epirubicin 25 mg/m2 D1,8,15 to with 2 days of Neupogen  Exam improve

**Type_of_Cancer**: = (完全一致)

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: ⚠️ HF更长(22 vs 13)
- vLLM: Yes, to liver
- HF: Yes, to multiple sites

**response_assessment**: ⚠️ HF更长(442 vs 119)
- vLLM: Liver smaller and feels less tender or bloated. No significant physical exam findings of concern. Tumor marker pending.
- HF: The cancer is currently stable on treatment. The patient is on Epirubicin Cycle#2 D1. Liver size has decreased and tenderness has reduced. No shortness of breath, nausea, or vomiting. Tumor marker levels are elevated, but no new masses, skin changes, or lymphadenopathy noted on physical exam. Labs s

**current_meds**: ⚠️ HF更长(25 vs 21)
- vLLM: Epirubicin, Denosumab
- HF: EPIRUBICIN HCL, DENOSUMAB

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Plan cycle#2 D1 Epirubicin 25 mg/m2 D1,8,15 to with 2 days of Neupogen. Okay to proceed with chemotherapy.
- HF: Plan cycle#2 D1 Epirubicin 25 mg/m2 D1,8,15 to with 2 days of Neupogen

**imaging_plan**: = (完全一致)

**lab_plan**: ≈ 相近
- vLLM: Labs liver functions, Tumor marker pending
- HF: Labs liver functions, tumor marker pending

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Plan cycle#2 D1 Epirubicin 25 mg/m2 D1,8,15 to with 2 days of Neupogen
- HF: Cycle #2: D1 Epirubicin 25 mg/m2, D1,8,15 with 2 days of Neupogen


---
## ROW 95
A/P摘要: "ASSESSMENT & PLAN  # Breast CA, Left  ***** ***** ***** is a 49 y.o. female with  left ER+/PR+/*****- breast cancer who started the ***** trial rando

**Type_of_Cancer**: ⚠️ HF更长(166 vs 78)
- vLLM: ER+/PR-/HER2- invasive ductal carcinoma with residual ductal carcinoma in situ
- HF: ER+/PR-/HER2- invasive ductal carcinoma with treatment effect, three foci, margins negative; residual ductal carcinoma in situ with treatment effect, margins negative

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Stage II (inferred from 2.1cm tumor)
- HF: Stage IIA (inferred from pT2 N1a)

**Distant Metastasis**: = (完全一致)

**response_assessment**: ✅ vLLM更详细
- vLLM: MRI breast: Interval decrease in irregularly shaped mass with irregular margins and heterogeneous internal enhancement in the left breast, now measuring 10 x 8 x 8mm, most recently 16 x 16 x 15mm. Posterior satellite decreased in size to 4 x 5 x 6mm. Improved, though not resolved, lower outer and lo
- HF: The cancer is responding to neoadjuvant therapy with a good response. Pathology results show residual invasive ductal carcinoma with treatment effect, three foci, margins negative; residual ductal carcinoma in situ with treatment effect, margins negative; residual invasive tumor cellularity: ~20% in

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Continue pembrolizumab. axilla XRT; patient prefers breast and axilla XRT and is referred to Rad Onc. Discuss option of capecitabine for residual disease post NAC based on CREATE-X trial; patient is interested and wishes to proceed with XRT next, then capecitabine. Strongly recommend adjuvant endocr
- HF: Start AC chemotherapy. Axilla XRT; patient is interested in breast and axilla XRT. Discuss option of capecitabine for residual disease post NAC based on CREATE-X trial; Patient wishes to proceed with XRT next, then capecitabine. Strongly recommend adjuvant endocrine therapy after the above.

**imaging_plan**: ⚠️ HF更长(53 vs 21)
- vLLM: breast and axilla XRT
- HF: Pt wishes to proceed with breast and axilla XRT next.

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ⚠️ HF更长(131 vs 64)
- vLLM: Continue prilosec 40mg qd, plan to start capecitabine after XRT.
- HF: Continue prilosec 40mg qd. Patient is interested in starting capecitabine for residual disease post NAC, to be initiated after XRT.


---
## ROW 97
A/P摘要: "- We reviewed the pathology results, clinical features and prognostic factors involved in her case. We also discussed the natural history and princip

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+/PR+/HER2- grade 1 invasive ductal carcinoma with low to intermediate nuclear grade DCIS
- HF: ER+/PR+/HER2- invasive ductal carcinoma

**Stage_of_Cancer**: ✅ vLLM更详细
- vLLM: Stage IA (pT1b N0)
- HF: pT1bN0(sn)

**Distant Metastasis**: = (完全一致)

**response_assessment**: = (完全一致)

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM更详细
- vLLM: Strongly recommend adjuvant endocrine therapy with [REDACTED] at the appropriate juncture. Do not anticipate any problem with MS regimen / gilenya and future endocrine therapy with [REDACTED]; physical therapy
- HF: do not anticipate any need for chemotherapy; no problem with MS regimen / gilenya and future endocrine therapy with [REDACTED]

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: ✅ vLLM更详细
- vLLM: Patient wishes to proceed with molecular profiling, e.g. Oncotype Dx assay.
- HF: molecular profiling

**medication_plan**: ✅ vLLM更详细
- vLLM: Strongly recommend adjuvant endocrine therapy with [REDACTED] at the appropriate juncture. Continue ongoing GILENYA regimen. Do not anticipate any problem with MS regimen / gilenya and future endocrine therapy with [REDACTED].
- HF: Continue with ongoing GILENYA regimen. No changes to MS medication regimen anticipated in relation to future endocrine therapy.

**→ ALL-WIN ✅**

---
## ROW 100
A/P摘要: "ASSESSMENT & PLAN  Breast cancer metastasized to multiple sites  Tumor markers rose initally with switch to Gemzar up double from beginning of year  

**Type_of_Cancer**: ✅ vLLM更详细
- vLLM: ER+(80%)PR+(50%) HER2- grade 2 invasive ductal carcinoma with metastatic recurrence to multiple sites
- HF: ER+(80%)PR+(50%)HER2- invasive ductal carcinoma

**Stage_of_Cancer**: = (完全一致)

**Distant Metastasis**: ⚠️ HF更长(32 vs 22)
- vLLM: Yes, to liver and bone
- HF: Yes, to liver and multiple sites

**response_assessment**: ✅ vLLM更详细
- vLLM: Tumor markers elevated: Cancer Antigen 15-3 at 118 U/mL (<33 U/mL), Cancer Antigen 27.29 at 178 U/mL (<39 U/mL). Elevated levels of Alkaline Phosphatase at 172 U/L (31-95 U/L) and AST at 57 U/L (17-42 U/L). Bilirubin, total at 0.7 mg/dL (0.2-1.3 mg/dL) within normal range. Urea Nitrogen at 23 mg/dL 
- HF: Tumor markers (Cancer Antigen 15-3 and Cancer Antigen 27.29) have increased. The current picture is unclear if the disease is progressing or showing a tumor flare. No new imaging findings are mentioned in the note to assess the response to Gemzar.

**current_meds**: = (完全一致)

**goals_of_treatment**: = (完全一致)

**therapy_plan**: ✅ vLLM独有
- vLLM: Rec exercise 10 min 3 x a day, Focalin prn and continue with treatment to see if
- HF: (空)

**imaging_plan**: = (完全一致)

**lab_plan**: = (完全一致)

**genetic_testing_plan**: = (完全一致)

**medication_plan**: ✅ vLLM更详细
- vLLM: Continue with treatment, Focalin prn for fatigue.
- HF: Focalin prn to address fatigue.

